Scott T. Garrett - 22 May 2026 Form 4 Insider Report for HCW Biologics Inc. (HCWB)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
27 May 2026, 19:25:09 UTC
Prior SEC filing
20 May 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Nicole Valdivieso, as Attorney-in-Fact for Scott T. Garrett

Key filing fact

Scott T. Garrett filed Form 4 for HCW Biologics Inc. (HCWB) on 27 May 2026.

Key facts

  • This page summarizes Scott T. Garrett's Form 4 filing for HCW Biologics Inc. (HCWB).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 27 May 2026, 19:25.

Change

  • Previous filing in this sequence was filed on 20 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001231174 Primary reporting owner

GARRETT SCOTT T

Relationship
Director
Address
C/O HCW BIOLOGICS INC., 2929 N. COMMERCE PARKWAY, MIRAMAR,
Signature
/s/ Nicole Valdivieso, as Attorney-in-Fact for Scott T. Garrett
Signature date
27 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HCWB transaction

Common Stock

Purchase

Transaction value
Shares
+177,936
Change %
+698%
Price
$1.40*
Shares after
203,441
Date
22 May 2026
Ownership
By LLC
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HCWB transaction Derivative

Common Stock Purchase Warrant

Purchase

Transaction value
Shares
+177,936
Change %
+6610%
Price
$0.000000*
Shares after
180,628
Date
22 May 2026
Ownership
By LLC
Underlying class
Common Stock
Underlying amount
177,936
Exercise price
$1.28
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reporting person purchased these shares directly from the issuer in a private placement, which purchase is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .